<i>In Vivo</i> Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix.

ABSTRACT: Protease inhibitors (PIs) are the second- and last-line therapy for the majority of HIV-infected patients worldwide. Only around 20% of individuals who fail PI regimens develop major resistance mutations in protease. We sought to explore the role of mutations in gag-pro genotypic and phenotypic changes in viruses from six Nigerian patients who failed PI-based regimens without known drug resistance-associated protease mutations in order to identify novel determinants of PI resistance. Target enrichment and next-generation sequencing (NGS) with the Illumina MiSeq system were followed by haplotype reconstruction. Full-length Gag-protease gene regions were amplified from baseline (pre-PI) and virologic failure (VF) samples, sequenced, and used to construct gag-pro-p

SUBMITTER: Datir R 

PROVIDER: S-EPMC7642677 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature